Stablix logo

Stablix

New York, NY

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

stablix.com

Company Details

Founded

2021

Employees

Between 20 - 50 employees

Raised

$63,000,000

Headquarters Location

New York, NY

Public

No

Acquired

No

CEO

Tony KingsleyTony Kingsley

Founders

Scott Kanner
Scott Kanner
Kevin Sprott
Kevin Sprott
Brian Bowman
Brian Bowman
Henry Colecraft
Henry Colecraft
Carlo Rizzuto
Carlo Rizzuto

Company Collections

These are collections Stablix is a part of. Click on the collection name to view similar companies.

Stablix's Industries

Stablix's Tech Stack

Stablix Headquarters Location

3960 Broadway 6th Floor, New York, NY 10032

Total Amount Raised: $63,000,000

Stablix Funding Rounds

  • Series A

    $63,000,000

    Series A Investors

    Versant Ventures
    NEA - New Enterprise Associates
    Cormorant Asset Management
    Alexandria Real Estate Equities
    Euclidean Capital
Funding info provided by Diffbot.

Stablix Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Stablix.

Recent reviews